Starpharma’s COVID Nasal Spray Launched In UK
Australia's Starpharma has launched in the UK its Viraleze antiviral COVID-19 nasal spray. On pack messaging states that the product "inactivates respiratory viruses, including >99.9% of coronavirus SARS-CoV-2."
You may also be interested in...
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?
COV-Defense nasal spray, claimed to inactivate the SARS-CoV-2 virus, will no longer launch in France after regulator ANSM demanded rigorous efficacy and safety data.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.